文献速递免疫规划传染病防控与疫情报告

超越中和抗体:减毒四价登革热疫苗体液免疫评估综合框架

Beyond neutralization: A comprehensive framework for evaluating humoral immunity induced by a live-attenuated tetravalent dengue vaccine.
PubMed 文献 · Vaccine · 2026-07-21

本研究基于TAK-003疫苗多项临床试验样本,采用微量中和试验、总结合IgG ELISA、抗登革补体抗体试验、抗NS1 IgG ELISA和IgG亲和力试验评估体液免疫应答。结果显示疫苗接种诱导四种血清型多重非重叠抗体应答,基线血清阳性者应答幅度更高但疫苗效应在血清阴性者更强,提示中和抗体外参数应纳入评估。

要点

  • TAK-003诱导四种登革血清型的多重非重叠体液免疫应答
  • 基线血清阳性者应答幅度更高,但疫苗效应在血清阴性者更强
  • 建议中和抗体外纳入总结合IgG、抗NS1 IgG等参数评估疫苗应答

核心结论

  • TAK-003疫苗接种诱导多重非重叠、独特的体液免疫应答,支持在中和抗体外纳入其他参数以更全面评估疫苗诱导的体液应答。

研究设计与样本

  • 研究采用微量中和试验、登革总结合IgG ELISA、抗登革补体抗体试验、抗登革NS1 IgG ELISA和抗登革IgG亲和力试验,检测多项TAK-003疫苗临床试验中疫苗接种组与安慰剂组参与者的样本。

主要发现

  • 疫苗接种诱导所有四种登革血清型在各检测中均产生应答,基线血清阳性者应答幅度更高,但疫苗效应在基线血清阴性者更强。
  • 基线血清阴性者各血清型的登革总结合IgG浓度、抗登革IgG亲和力和抗登革补体抗体滴度应答相当。
  • MNT50中和抗体和抗登革NS1 IgG应答因血清型而异。
  • 各参数间相关性为中低水平,提示不同检测测量的是非冗余的疫苗诱导体液免疫应答。
  • 应答变异的主要来源为接种后时间,其次为血清型。

临床怎么用

  • 评估登革热疫苗体液免疫时,除中和抗体外可考虑纳入总结合IgG、抗NS1 IgG、补体抗体和IgG亲和力等参数。
  • 解读疫苗应答时需考虑基线血清状态、血清型和接种后时间对结果的影响。

局限性

  • 原文未明确报告免疫学保护相关物,不同检测间相关性仅为中低水平,综合框架仍需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Dengue incidence is increasing worldwide. TAK-003, a live-attenuated tetravalent dengue vaccine, is licensed in several countries. Its safety, efficacy, and immunogenicity have been extensively studied and provided the roadmap for recommendations and implementation. Per WHO guidelines, the primary immunogenicity endpoint in dengue vaccine clinical trials is neutralizing antibody (NAb) titers. However, there is no established immunological correlate of protection, and dengue virus (DENV) elicits a broad range of antibody responses. This study assessed statistical and experimental methods to evaluate a wide range of antibody responses to TAK-003 as a framework for evaluating vaccine immunological signatures that may correlate with protection from dengue infection and/or disease. METHODS: Responses were assessed by the following immunoassays: microneutralization assay, DENV total binding IgG ELISA, anti-dengue complement antibody assay, anti-dengue non-structural protein 1 (NS1) IgG ELISA, and anti-dengue IgG avidity assay. Samples from TAK-003 vaccinated/placebo participants from several trials were tested. Results were compared for assay performance and the impact of baseline serostatus, serotype, and age on vaccine-elicited responses. Correlation analyses assessed relationships among variables. Principal component analyses (PCA) evaluated data complexity. RESULTS: Vaccination elicited responses to all four DENV serotypes in each assay. The magnitude of vaccine-induced responses was higher in baseline seropositive participants, but vaccine effect was stronger in baseline seronegative participants. Baseline seronegative participants had comparable DENV total binding IgG concentrations, anti-dengue IgG avidity, and anti-dengue complement antibody titer responses across all serotypes. MNT50 NAb and anti-dengue NS1 IgG responses varied by serotype. Modest to low correlations across parameters suggest that the different assays measure non-redundant vaccine-induced humoral immune responses. The major source of response variability was post-vaccination time, followed by serotype. CONCLUSION: TAK-003 vaccination elicited multiple non-overlapping, unique humoral immune responses. Data support including parameters in addition to NAbs to better assess vaccine-induced humoral responses. CLINICALTRIALS: govregistration:NCT01511250, NCT02302066, NCT02747927, NCT03423173.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Gottardo R, Dean H, Nascimento EJM, et al. Beyond neutralization: A comprehensive framework for evaluating humoral immunity induced by a live-attenuated tetravalent dengue vaccine. Vaccine. 2026. PMID: 42480195. doi:10.1016/j.vaccine.2026.128929

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。